AMG 557/MEDI5872 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
53	Sjogren syndrome	2

53. Sjogren syndrome

---

Clinical trials : 305 /  Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02334306 (ClinicalTrials.gov)	June 8, 2015	12/12/2014	A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome	A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome	Primary Sjögren's Syndrome	Biological: AMG 557/MEDI5872;Other: Placebo	MedImmune LLC	Amgen	Completed	18 Years	75 Years	All	32	Phase 2	United States;France;Sweden;United Kingdom
2	EUCTR2014-003896-41-GB (EUCTR)	27/03/2015	05/02/2015	MedImmune Sjogren's Syndrome Study	A Phase 2a, Randomized, Placebo-controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects with Primary Sjogren’s Syndrome	Primary Sjogren’s Syndrome MedDRA version: 18.1;Level: LLT;Classification code 10042846;Term: Syndrome Sjogren's;System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: AMG 557/MEDI5872 Product Code: AMG 557/MEDI5872 INN or Proposed INN: AMG 557/MEDI5872	MedImmune, LLC	NULL	Not Recruiting			Female: yes Male: yes	42	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	France;United States;United Kingdom;Sweden